Piper Sandler ups Intra-Cellular to obese, cites Caplyta potential Source: Seekingalpha
Browsing: cites
Stifel starts ORIC at purchase, cites prostate cancer drug candidate Source: Seekingalpha
Piper Sandler ups Intra-Cellular to chubby, cites Caplyta potential Source: Seekingalpha
Stifel starts ORIC at purchase, cites prostate cancer drug candidate Source: Seekingalpha
Piper Sandler ups Intra-Cellular to obese, cites Caplyta potential Source: Seekingalpha
Stifel starts ORIC at purchase, cites prostate cancer drug candidate Source: Seekingalpha
Roth starts CG Oncology at purchase, cites anticipated FDA filing Source: Seekingalpha
peterschreiber.media BofA began protection of Biohaven (NYSE:BHVN) with a purchase ranking, citing its drug improvement applications for temper and autoimmune problems. The funding financial institution mentioned…
peterschreiber.media BofA began protection of Biohaven (NYSE:BHVN) with a purchase ranking, citing its drug improvement applications for temper and autoimmune issues. The funding financial institution mentioned…
peterschreiber.media BofA began protection of Biohaven (NYSE:BHVN) with a purchase score, citing its drug improvement packages for temper and autoimmune problems. The funding financial institution mentioned…